Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
43281
The kinetics of the linear component affect the peak frequency of a bell shaped response.
Published 2014“…(<b>B</b>) The corresponding bell-shaped responses have a peak that shifts to the right accordingly. (<b>C</b>) Duration compensation: increasing τ<sub>a</sub> shifts the response in </a><a><sub>on,∞</sub> and its K crossing point to the right. …”
-
43282
-
43283
Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf
Published 2021“…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
-
43284
Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf
Published 2021“…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
-
43285
Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf
Published 2021“…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
-
43286
Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf
Published 2021“…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
-
43287
-
43288
DataSheet_1_Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.pdf
Published 2022“…Prophylactic treatment with GG showed protection against loss in body weight and a 35%–40% decrease in lung viral load along with reduced lung pathology in the hamster model. …”
-
43289
Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation
Published 2017“…Sheep were randomly allocated to two groups: 1) ASCs: infused with 200 million of ASCs in 200mL of PlasmaLyteA starting 1 hours post-injury, n = 5; 2) control, treated with 200mL of PlasmaLyteA in a similar pattern, n = 5.…”
-
43290
Image_2_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif
Published 2022“…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
-
43291
Illustration of three simple scenarios of association between genotype and a bivariate phenotype.
Published 2013“…A) A variant associated with <i>weight</i> but not <i>height</i>. …”
-
43292
Image_1_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif
Published 2022“…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
-
43293
Inc exhibits key properties of a Cul3 adaptor in neurons in vivo.
Published 2025“…<p><b>(A)</b> Co-immunoprecipitation of 3×FLAG-Inc and 3×FLAG-3×HA-Cul3 from male whole animal lysates. …”
-
43294
Image_4_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif
Published 2022“…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
-
43295
Associations between HbA1c levels and mortality and diabetes complications.
Published 2025“…The risk increases steadily with increasing HbA1c levels, with no clear inflection point. D: RCS curves for CKD risk. …”
-
43296
Image_6_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif
Published 2022“…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
-
43297
Image_3_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif
Published 2022“…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
-
43298
-
43299
-
43300